Autoimmunity BioSolutions

Based in Houston, US, and founded in 2016 by co-founder and CSO Gaddiel Galarza-Munoz, Autoimmunity Biologic Solutions, Inc. , trading under the name Autoimmunity BioSolutions operates as a biotechnology company that focuses on developing immuno-corrective therapy for genetically-defined subpopulations of patients that suffer from autoimmune disease. In May 2026, Autoimmunity BioSolutions raised USD 1 million in seed funding led by Eos BioInnovation, with particicpation from investor Independent Capital Group, NewTech Investment Holdings. The round was part of a larger USD 3.

1 million seed funding. The company will use the funding to conduct preclinical studies, including animal testing and analysis of patient samples for its autoimmune therapy program. Autoimmunity Biologic Solutions, Inc. specializes in the development of a next-generation immunocorrective therapy aimed at restoring normal immune function specifically for a genetically defined subpopulation of autoimmune disease patients.

The company’s core product, the anti-sIL7R therapy, targets the autoimmune pathology associated with a single nucleotide polymorphism (SNP) that leads to the upregulation of the soluble interleukin 7 receptor (sIL7R). This therapy is designed to serve individuals suffering from various autoimmune diseases who exhibit elevated levels of sIL7R due to this genetic marker. The primary markets for these therapeutic offerings include regions with high prevalence of autoimmune diseases, particularly in North America and Europe. The company plans to use its proceeds from September 2025 funding to commercialize its therapy for autoimmune diseases and introduce multiple sclerosis treatment into the Japanese healthcare sector.

The revenue generation model for Autoimmunity Biologic Solutions, Inc. revolves around the commercialization of its anti-sIL7R therapy, with a focus on establishing partnerships with healthcare providers and pharmaceutical companies. The transaction structure is primarily B2B, facilitating the distribution of therapies through healthcare networks and specialty pharmacies. Revenue is derived from direct sales to healthcare institutions and clinics, which prescribe the therapy to eligible patients based on genetic testing that identifies the SNP and high sIL7R levels.